Cue Biopharma, Inc. $CUE Stake Cut by Renaissance Technologies LLC

Renaissance Technologies LLC cut its holdings in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 10.3% in the first quarter, HoldingsChannel reports. The fund owned 213,828 shares of the company’s stock after selling 24,526 shares during the quarter. Renaissance Technologies LLC owned 0.05% of Cue Biopharma worth $49,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma during the third quarter worth approximately $62,000. Boothbay Fund Management LLC purchased a new position in Cue Biopharma during the third quarter valued at approximately $439,000. GC Wealth Management RIA LLC grew its position in Cue Biopharma by 35.0% during the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock valued at $1,415,000 after purchasing an additional 1,200,000 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc increased its stake in Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after buying an additional 407,568 shares during the period. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a report on Thursday, August 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cue Biopharma presently has an average rating of “Sell”.

Insider Buying and Selling at Cue Biopharma

In other Cue Biopharma news, insider Sumita Ray sold 8,829 shares of Cue Biopharma stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $265,664.61. Following the completion of the sale, the insider directly owned 118,545 shares in the company, valued at $3,567,019.05. The trade was a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Shao-Lee Lin sold 18,258 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $28.62, for a total transaction of $522,543.96. Following the completion of the sale, the chief executive officer directly owned 705,995 shares of the company’s stock, valued at $20,205,576.90. This represents a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 72,715 shares of company stock worth $2,041,555 over the last ninety days. 14.56% of the stock is currently owned by insiders.

Cue Biopharma Price Performance

CUE opened at $23.98 on Friday. The company has a market capitalization of $174.09 million, a PE ratio of -0.89 and a beta of 2.47. Cue Biopharma, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $45.50. The business has a 50-day moving average of $29.28 and a 200-day moving average of $136.71.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. The firm had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million.

Cue Biopharma Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.